HanAll Biopharma Co Ltd (009420):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:HanAll Biopharma Co Ltd (009420) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3489
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
HanAll Biopharma Co Ltd (HanAll), formerly HanAll Pharmaceutical Co Ltd, is a pharmaceutical company that offers drug delivery, biotherapeutics, and small molecule discovery programs. The company develops drugs in therapeutic areas of ophthalmology, immunology, cardiovascular disease, dermatology and biobetter. It offers drug research and development, medical information and advanced products. HanAll operates through its research and development center and biotechnology research institute. The company’s products are used in treatment of autoimmune diseases, dry eye diseases, and recurrent and intractable cancer. It has operations in South Korea and the US. HanAll is headquartered in Seoul, South Korea.

HanAll Biopharma Co Ltd (009420) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
HanAll Biopharma Enters into Licensing Agreement for OmniAb Antibody 11
Roivant Sciences Enters into Licensing Agreement with HanAll Biopharma 12
Harbour BioMed Enters into Licensing Agreement with HanAll Biopharma 13
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 14
Equity Offering 15
Hanall Biopharma to Raise USD0.3 Million in Public Offering of Shares 15
Acquisition 16
Yuhan Completes Acquisition Of 9.1% Stake In Hanall For US$27 Million 16
HanAll Biopharma Co Ltd – Key Competitors 17
HanAll Biopharma Co Ltd – Key Employees 18
HanAll Biopharma Co Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
HanAll Biopharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
HanAll Biopharma Enters into Licensing Agreement for OmniAb Antibody 11
Roivant Sciences Enters into Licensing Agreement with HanAll Biopharma 12
Harbour BioMed Enters into Licensing Agreement with HanAll Biopharma 13
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 14
Hanall Biopharma to Raise USD0.3 Million in Public Offering of Shares 15
Yuhan Completes Acquisition Of 9.1% Stake In Hanall For US$27 Million 16
HanAll Biopharma Co Ltd, Key Competitors 17
HanAll Biopharma Co Ltd, Key Employees 18
HanAll Biopharma Co Ltd, Other Locations 19

List of Figures
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
HanAll Biopharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[HanAll Biopharma Co Ltd (009420):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Yue Yuen Industrial (Holdings) Limited:企業の戦略・SWOT・財務情報
    Yue Yuen Industrial (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Yue Yuen Industrial (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Trent Limited (TRENT):企業の財務・戦略的SWOT分析
    Trent Limited (TRENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Grupo Posadas Sab De Cv:企業の戦略・SWOT・財務分析
    Grupo Posadas Sab De Cv - Strategy, SWOT and Corporate Finance Report Summary Grupo Posadas Sab De Cv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BioIQ Inc:医療機器:M&Aディール及び事業提携情報
    Summary BioIQ Inc (BioIQ) is a healthcare technology company that offers health and wellness programs. The company’s dimensions screening platforms comprise lab testing, physician results, at-home testing, and flu vaccinations, among others. It offers axis integration platforms such as Bioiq ecosyst …
  • Keepmoat Ltd:企業の戦略的SWOT分析
    Keepmoat Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Formosa Plastics Corp (1301):企業の財務・戦略的SWOT分析
    Formosa Plastics Corp (1301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Thoresen Thai Agencies Public Company Limited:企業の戦略・SWOT・財務情報
    Thoresen Thai Agencies Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Thoresen Thai Agencies Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • California Water Service Group (CWT):企業の財務・戦略的SWOT分析
    Summary California Water Service Group (California Water Service) is a utility service provider that offers wastewater services and water operation and maintenance services. The utility provides services such as water and wastewater utility services, and operating water and wastewater systems servic …
  • The Boeing Company:企業の戦略・SWOT・財務情報
    The Boeing Company - Strategy, SWOT and Corporate Finance Report Summary The Boeing Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Jones Packaging Inc:企業の戦略的SWOT分析
    Jones Packaging Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Banco Pan S.A. (BPAN4):企業の財務・戦略的SWOT分析
    Banco Pan S.A. (BPAN4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Merz Pharma GmbH & Co KgaA-医療機器分野:企業M&A・提携分析
    Summary Merz Pharma GmbH & Co KgaA (Merz Pharma) is an aesthetics and neurotoxin company that develops products for aesthetic and medical dermatology and neurological movement disorders. The company’s products include aesthetics, ethical drugs, over-the-counter drugs, neurology, and central nervous …
  • LG Chem Ltd (051910):企業の財務・戦略的SWOT分析
    LG Chem Ltd (051910) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • XOMA Corp (XOMA):企業の財務・戦略的SWOT分析
    XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bio-Alternative Medical Devices Ltd:企業の製品パイプライン分析2018
    Summary Bio-Alternative Medical Devices Ltd (Bio AMD), a subsidiary of Bio-AMD Inc, is a medical device company that designs, develops, and markets point of care medical diagnostic products. The company offers products such as blood coagulation monitor, digital strip reader, and magnetic immunoassay …
  • Juno Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells …
  • G3 Exploration Ltd (GDG):石油・ガス:M&Aディール及び事業提携情報
    Summary G3 Exploration Ltd (G3 Exploration), formerly Green Dragon Gas Ltd, is an oil and gas company that offers exploration and production of coal bed methane gas. The company offers services such as exploration, transportation fleet operations, retail CNG stations, and production programs, among …
  • BioLineRx Ltd (BLRX):医療機器:M&Aディール及び事業提携情報
    Summary BioLineRx Ltd (BioLineRx) is a clinical stage biopharmaceutical company that focuses on the identification, in-licensing, and development of products to address unmet medical needs. The company focuses mainly on cancer and immunology. Its’s product pipeline includes BL-8040, a short peptide …
  • Andhra Pradesh Power Generation Corp Ltd:企業の戦略的SWOT分析
    Andhra Pradesh Power Generation Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • E.ON SE (EOAN):企業の財務・戦略的SWOT分析
    E.ON SE (EOAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆